WO2026078620 - CD22 ANTIBODY AND DRUG CONJUGATES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/078620
Publication Date
16.04.2026
International Application No.
PCT/IB2025/060233
International Filing Date
09.10.2025
Title **
[English]
CD22 ANTIBODY AND DRUG CONJUGATES AND USES THEREOF
[French]
CONJUGUÉS ANTICORPS ANTI-CD22-MÉDICAMENT AINSI QUE LEURS UTILISATIONS
Applicants **
MEDIMMUNE LLC
Inventors
MARELLI, Marcello
HAN, Huiying
DU, Qun
Priority Data
63/706,134
11.10.2024
US
63/718,026
08.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5569 | |
| EPO | Filing, Examination, Granting | 96254 | |
| Japan | Filing, Examination, Granting | 4848 | |
| South Korea | Filing, Examination, Granting | 7400 | |
| USA | Filing, Examination, Granting | 28640 |
Total:
142,711
Contact Us
Abstract[English]
The present disclosure relates to CD22 binding molecules, such as anti-CD22 antibodies, for the treatment of cancer, and related antibody-drug conjugates.[French]
La présente divulgation concerne des molécules de liaison à CD22, telles que des anticorps anti-CD22, pour le traitement du cancer, et des conjugués anticorps-médicament associés.